Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
Rhea-AI Summary
Phio Pharmaceuticals (NASDAQ: PHIO) will present at the Sidoti Micro-Cap Virtual Investor Conference on January 22, 2026 at 1:45 PM ET. CEO and Chairman Robert Bitterman will provide an update on the company's proprietary INTASYL siRNA technology and progress in the ongoing clinical trial of lead compound PH-762 for treatment of skin cancers. The presentation is available via live webcast and the CEO will hold one-on-one investor meetings during the conference on Jan 21–22, 2026. Registration is free and open to non-clients.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
PHIO fell 5.08% while key biotech peers showed mixed moves (e.g., PHGE up 15.79%, ADAP down 17.57%, APLM down 6.64%). Only one peer (MRKR) appeared in momentum scans, up 4.07%, pointing to stock-specific rather than sector-driven dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Drug development update | Positive | -6.4% | FDA accepted nonclinical protocol and toxicology study planned for Q1 2026. |
| Nov 25 | Clinical trial progress | Positive | +3.5% | Completed enrollment in Phase 1b PH-762 trial across five dose cohorts. |
| Nov 17 | Conference presentation | Positive | +1.5% | Upcoming podium talk on INTASYL siRNA drug technology at industry congress. |
| Nov 13 | Earnings & update | Positive | -9.5% | Q3 2025 results, strong PH-762 responses, and financings lifting cash runway. |
| Nov 07 | Clinical data presentation | Positive | +5.4% | Planned SITC poster with Phase 1b PH-762 clinical results for skin cancers. |
Recent positive clinical and financing updates have produced mixed reactions, with several strong fundamental milestones followed by negative price moves.
Over the last few months, Phio has focused on advancing PH-762 and strengthening its balance sheet. On Nov 3 and Nov 25, the company highlighted encouraging Phase 1b data and completion of enrollment, and on Dec 23 it announced FDA acceptance of a nonclinical protocol with toxicology work expected in Q1 2026. Financing steps and Q3 2025 results on Nov 13 added cash and extended runway. Today’s conference participation fits a pattern of active scientific and investor outreach around PH-762 and INTASYL technology.
Regulatory & Risk Context
An effective resale registration on Form S-3 covers up to 11,763,800 warrant shares. While the company does not sell shares under this prospectus, full cash exercise of the warrants would provide up to $24.5 million in proceeds to support working capital and PH-762 development. Existing holders, not the company, may resell the registered shares.
Market Pulse Summary
This announcement centers on Phio’s participation in an investor conference, providing a platform to highlight INTASYL siRNA technology and PH-762 clinical progress. It follows recent milestones, including completion of Phase 1b enrollment and FDA acceptance of a nonclinical protocol in Q1 2026. Investors may monitor upcoming PH-762 toxicology work, further Phase 1b readouts, and any updates around the warrant-related S-3 registration for signals on development trajectory and funding flexibility.
Key Terms
sirna medical
gene silencing medical
AI-generated analysis. Not financial advice.
Registration Link for Phio's Presentation on Thursday, January 22 at 1:45 PM ET
King of Prussia, Pennsylvania--(Newsfile Corp. - January 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers.
"All stakeholders and investors are invited to join the presentation and register for one-on-one meetings to learn more about Phio Pharmaceuticals in our continuing pursuit of innovative pathways towards a cancer free future using our INTASYL technology," stated Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.
Phio's presentation will begin at 1:45 PM ET on January 22, 2026 and can be accessed live here: WEBCAST LINK FOR PHIO'S PRESENTATION: Webinar Registration - Zoom
Mr. Bitterman will also host one-on-one meetings with investors at the conference, taking place on Wednesday Jan 21, 2026 8:30 AM ET through Thursday Jan 22, 2026 at 5:00 PM ET. Registration is free and you don't need to be a Sidoti client. REGISTRATION LINK FOR ONE-ON-ONE MEETINGS: www.sidoti.com/events.
About Sidoti Events, LLC ("Events") and Sidoti & Company, LLC ("Sidoti")
In 2023, Sidoti & Company, LLC , Sidoti & Company, LLC (www.sidoti.com) formed an affiliate company, Sidoti Events, LLC in order to focus exclusively on its rapidly growing conference business and to more directly serve the needs of presenters and attendees. The relationship allows Events to draw on the 25 years of experience Sidoti has as a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest in their securities, with most of its coverage in the
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The ongoing Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells, the potential for PH-762 to present a viable non-surgical alternative for skin cancer, expectations regarding timing of enrollment, the expectations that we have sufficient capital to complete the treatment phase of our ongoing Phase 1b clinical trial, and statements regarding our clinical strategy, development plans and timelines and other future events.
These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, results from our preclinical and clinical activities, our ability to execute on business strategies, the timing or likelihood of regulatory filings and approvals, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280343
FAQ
When will Phio (PHIO) present at the Sidoti Micro-Cap Virtual Investor Conference?
Who will present Phio's update at the PHIO conference on January 22, 2026?
What topics will Phio (PHIO) cover in the January 22, 2026 presentation?
Can investors schedule one-on-one meetings with Phio (PHIO) at the Sidoti conference?
Is registration required and is there a fee to attend Phio's (PHIO) webcast on January 22, 2026?
How can investors access Phio's (PHIO) live webcast on January 22, 2026?
